Vizient Quality and Accountability Ranking. Ranked #1 out of 115 participating comprehensive academic medical centers." ...

Corbus Pharmaceuticals presented Phase 1 data on CRB-701 at ASCO GU, showing safety, tolerability, and responses across multiple tumor types.

Moderna is now expecting 2025 research and development costs of about $4.1 billion and selling, general and administrative costs of about $1.1 billion. Cost of sales is expected to come to about $1.2 ...

Two months after Allogene abandoned plans for its CAR-T in leukemia, analysts have suggested that fresh phase 1 data in ...

Patients Achieved Remission Within 30 Days in Cohort 1 of the Mipletamig RAINIER Dose Optimization Trial for Frontline AML Patients, Trial Enrollment Continues Promising Data, including a 59% Stable ...

Clinical trials have been pivotal to the improvements in public health and clinical care, leading to many millions of ...

The funding will be used to complete the Phase II/III trial of ulviprubart, and to support commercial launch preparation.

Valuation discrepancies in the biotech sector highlight Shuttle Pharma’s incredible potential. With several peer companies in ...

Lion TCR announced that its mRNA-encoded T-cell receptor (TCR)-T cell therapy product Liocyx-M004 has received clearance from ...